LivaNova: “FDA’s Warning Letter can be resolved without material impact on financial results”
LivaNova said that FDA’s Warning Letter can be resolved without a material impact on financial results.
Pharmaceuticals, Biotechnology and Life Sciences
LivaNova said that FDA’s Warning Letter can be resolved without a material impact on financial results.
Glenmark confirms reaching agreement with Roche over patent disputes
Suven Life Sciences Ltd has announced that the grand of one product patent from Canada, one from ARIPO and one from South Korea corresponding to the New Chemical Entities for the treatment of disorders associated with Neurodegenerative diseases and these Patents are valid through 2030.
Brooks Laboratories’ new manufacturing unit in Vadodra to kick off production in 3 months
India’s Dr. Reddy’s has re-launched its Esomeprazole Magnesium Delayed-Release Capsules, which is a therapeutic equivalent generic version of Nexium Delayed-Release…
Midatech Pharma, the international specialty pharmaceutical company focused on developing and commercialising products in oncology and other therapeutic areas, has…
Suven Life Sciences Ltd (SUVEN) has got the grant of one product patent from Europe and one product patent from Macau corresponding to the New Chemical Entities (NCEs) for the treatment of disorders associated with Neurodegenerative diseases and these Patents are valid through 2030 and 2029.
Nectar Lifesciences appoints Additional Independet Director
Glenmark Pharmaceuticals Inc., USA has been granted final approval by the United States Food & Drug Administration (U.S. FDA) for Linezolid Tablets, 600 mg, the therapeutic equivalent of Zyvox Tablets, 600 mg of Pharmacia and Upjohn Company, a subsidiary of Pfizer, Inc.
Aurobindo Pharma Limited has received final approval from the US Food & Drug Administration (USFDA) to manufacture and market Olopatadine Hydrochloride Ophthalmic Solution USP, 0.1% which makes the product is ready for launch.